Skip to main content

Advertisement

Table 4 Mean change from baseline in BCVA at 6 months

From: Ranibizumab for macular edema secondary to retinal vein occlusion: a meta-analysis of dose effects and comparison with no anti-VEGF treatment

Outcome of interest Studies (n) WMD (95% CI) P Study heterogeneity
χ 2 P I 2
IVR 0.5 mg vs non-anti-VEGF       
Type of RVO       
  All trials 4 12.30 (10.03,14.58) <0.001 1.66 0.646 0.00%
  CRVO 2 14.05 (10.54, 17.56) <0.001 0.02 0.900 0.00%
  BRVO 2 11.05 (8.07, 14.02) <0.001 0.01 0.933 0.00%
Sample size       
  All trials 4 12.30 (10.03,14.58) <0.001 1.66 0.646 0.00%
  >100 2 12.43 (9.40, 15.46) <0.001 1.61 0.205 37.9%
  <100 2 11.74 (3.98, 19.51) <0.001 0.03 0.868 0.00%
Different non-anti-VEGF treatment       
  All trials 4 12.30 (10.03,14.58) <0.001 1.66 0.646 0.00%
  Sham 3 12.37 (10.02, 14.72) <0.001 1.62 0.446 0.00%
  Sham plus laser 1 11.40 (2.64, 20.16) 0.011   -  
IVR 0.5 mg vs IVR 0.3 mg 2 1.90 (−0.35, 4.16) 0.098 0.05 0.831 0.00%
IVR 0.3 mg vs non-anti-VEGF 2 10.26 (7.80, 12.72) <0.001 1.11 0.293 9.50%
  1. BCVA = best-corrected visual acuity; WMD = weighted mean differences; OR = odds ratio; CI = confidence interval; IVR = intravitreal ranibizumab; VEGF = vascular endothelial growth factor; RVO = retinal vein occlusion; CRVO = central retinal vein occlusion; BRVO = branch retinal vein occlusion.